Photo of Keith W Pratz from X
Aug 14, 2024, 07:20
Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax
Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on X:
“Happy to share novel risk signature for AML treated with Azacitidine and Venetoclax. These data derived from VIALE-A trial demonstrate mutations in four genes (TP53, FLT-3, KRAS, and NRAS) predict patient outcomes more definitively than ELN2022 or ELN 2017.”
Source: Keith W Pratz/X
Authors: Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Christan Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea
AML
Andre C. Schuh
Andrew H. Wei
azacitidine
Brenda Chyla
Brian A. Jonas
cancer
Christan Récher
Courtney D. DiNardo
Daniel A. Pollyea
Grace Ku
Hartmut Döhner
Jalaja Potluri
Keith W. Pratz
Leukemia
Michael J. Thirman
Monique Dail
OncoDaily
Oncology
Penn Medicine
Sunil Babu
venetoclax
Vinod Pullarkat
Xiaotong Li
Yan Sun
Zihuan Liu